AADCL3 (ADCL3_HUMAN) as a Potential Drug Target and Biomarker

Target Name: AADACL3

NCBI ID: G126767

AADACL3

AADCL3 (ADCL3_HUMAN) as a Potential Drug Target and Biomarker

The protein AADCL3 (ADCL3_HUMAN) is a member of the AADCL3 family, which is primarily expressed in the brain and nervous system. The functions of AADCL3 and its associated diseases are not well understood, but its potential role as a drug target or biomarker is of great interest. In this article, we will explore the potential implications of AADCL3 as a drug target and biomarker.

Potential Drug Target

AADCL3 is known to play a critical role in the regulation of synaptic plasticity and neural development. It has been shown to interact with various signaling pathways, including the tiehlinger-zinn-hacklian pathway. This pathway is involved in the regulation of dopamine release and uptake, which are crucial for the formation and maintenance of neural circuits.

AADCL3 has been shown to regulate the tiehlinger-zinn-hacklian pathway by modulating the activity of several key proteins, including TrkB, a critical protein involved in dopamine release. AADCL3 has been shown to inhibit the activity of TrkB and increase the activity of another protein called P21, which is involved in the regulation of dopamine uptake.

In addition to its role in modulating dopamine signaling, AADCL3 has also been shown to play a critical role in the regulation of neurotransmitter release and synaptic plasticity. It has been shown to interact with multiple neurotransmitter receptors, including dopamine, serotonin, and GABA.

Potential Biomarker

AADCL3 is also of interest as a potential biomarker for various neurological disorders, including Alzheimer's disease. Alzheimer's disease is a neurodegenerative disorder characterized by the progressive loss of brain cells, including neurons and glial cells.

AADCL3 has been shown to be abnormally expressed in the brains of individuals with Alzheimer's disease, and several studies have suggested that it may play a role in the development and progression of this disease. In addition, AADCL3 has also been shown to be involved in the regulation of neurodegeneration, which is a common finding in Alzheimer's disease.

Conclusion

In conclusion, AADCL3 is a protein that has significant implications as a drug target and biomarker. Its role in the regulation of synaptic plasticity, dopamine signaling, and neurotransmitter release makes it an attractive target for drug development. Additionally, its involvement in the regulation of neurodegeneration and its abnormally expressed levels in the brains of individuals with Alzheimer's disease make it a promising biomarker for this disease. Further research is needed to fully understand the role of AADCL3 in these processes and its potential as a drug target and biomarker.

Protein Name: Arylacetamide Deacetylase Like 3

The "AADACL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AADACL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets